TrialHaematologica2024

Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study.

Verónica González-Calle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.